Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Can-Fite BioPharma’s risk-heavy biotech disclosures can feel like decoding lab notes. Clinical trial timelines, dilution clauses and revenue-sharing terms hide deep in each page. That complexity is why investors search for “Can-Fite BioPharma SEC filings explained simply” and “understanding Can-Fite BioPharma SEC documents with AI.”
Stock Titan turns that challenge into clarity. Our AI reads every new 10-K, 10-Q and 8-K the moment it posts to EDGAR, then highlights what matters for a clinical-stage company: R&D burn rate, Phase III milestones, cash runway and licensing revenue. Need the “Can-Fite BioPharma quarterly earnings report 10-Q filing” or an instant view of “Can-Fite BioPharma 8-K material events explained”? It’s one click away, already summarized in plain English.
Executive moves move micro-cap prices. Track “Can-Fite BioPharma insider trading Form 4 transactions” with real-time alerts. Our dashboard links every “Can-Fite BioPharma executive stock transactions Form 4” to trial announcements so you spot patterns early. Looking for board pay details? The latest “Can-Fite BioPharma proxy statement executive compensation” is tagged and translated into transparent tables.
Whether you’re comparing pipeline spending across quarters, assessing dilution risk, or needing a “Can-Fite BioPharma annual report 10-K simplified,” Stock Titan delivers. AI-powered summaries, expert context, and comprehensive coverage of all filings—so you spend minutes, not hours, on “Can-Fite BioPharma earnings report filing analysis.”
Can-Fite BioPharma Ltd. furnished a report noting that it issued a press release titled “Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change.” The company states that this press release, dated December 23, 2025, is incorporated by reference into its existing Form S-8 and Form F-3 registration statements. The report is signed by Motti Farbstein, who serves as both Chief Executive Officer and Chief Financial Officer.
Can-Fite BioPharma Ltd. changed the terms of an existing warrant package covering 16,666,666 American Depositary Shares. On November 18, 2025, the company agreed with the warrant holder to lower the exercise price on these warrants from $0.60 per ADS to $0.467 per ADS. In exchange, the holder waived certain standstill provisions, which had limited its actions in relation to the company. This adjustment makes it cheaper for the holder to exercise the warrants while releasing the company from the prior standstill constraints.
Can-Fite BioPharma Ltd. submitted a Form 6-K noting that it has furnished a press release as Exhibit 99.1. The press release, dated November 20, 2025, announces that Can-Fite’s CF602 erectile dysfunction treatment has received a notice of patent allowance in Brazil. The first paragraph of this press release is incorporated by reference into several of the company’s existing Form S-8 and Form F-3 registration statements.
Can-Fite BioPharma Ltd. (CANF) submitted a Form 6-K to furnish a new press release about its liver cancer drug candidate Namodenoson. The filing states that the first paragraph of the press release is incorporated by reference into several existing Form S-8 and Form F-3 registration statements, meaning that key descriptive information about the company and its programs is now formally part of those documents. The press release, titled “Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson,” highlights an advanced liver cancer patient who achieved 9-year survival with a complete cure while being treated with Namodenoson. The Form 6-K itself does not provide additional clinical data or financial details beyond announcing and cross-referencing this communication.
Can-Fite BioPharma Ltd. reported that shareholders approved both proposals presented at its Special General Meeting on November 10, 2025. The proposals were described in the company’s Notice and Proxy Statement dated October 3, 2025, which was furnished as Exhibit 99.1 to a prior Form 6-K on October 3, 2025.
Can-Fite BioPharma Ltd. adjourned its Special General Meeting of Shareholders due to lack of quorum and will reconvene on Monday, November 10, 2025 at 3:00 p.m. (Israel time) at the company’s offices, 26 Ben Gurion Street, Ramat Gan, Israel.
Can-Fite BioPharma Ltd. furnished a Notice and Proxy Statement, a Proxy Card for ordinary shareholders, and a Voting Instruction Card for American Depositary Shareholders in connection with a Special General Meeting of Shareholders. The report is dated October 3, 2025 and is signed by Motti Farbstein, who is listed as Chief Executive Officer and Chief Financial Officer. The filing incorporates prior registration statements by reference to the extent not superseded.
FAQ
What is the current stock price of Can-Fite BioPharma Ltd. (CANF)?
What is the market cap of Can-Fite BioPharma Ltd. (CANF)?
